Navigation Links
MedClean Technologies Inc. CEO Publishes Letter to Shareholders

President and CEO, Scott Grisanti, Publishes Letter Outlining Strategy, Market Opportunity and New Leadership Team

BETHEL, Conn., Feb. 12 /PRNewswire-FirstCall/ -- MedClean Technologies, Inc. (OTC Bulletin Board: MCLN), a provider of innovative technology and services for the onsite treatment and disposal of regulated medical waste, today announced that its President and CEO, Scott Grisanti, has published a letter to shareholders. The letter, which is available on the Company's website at, outlines MedClean's new strategy, the expanded, $2 billion annual opportunity for the Company's technology and expertise, its go-to-market strategy and the new leadership team in place to execute the strategic plan.

Mr. Grisanti commented, "The letter published today and mailed to shareholders discusses the Company's strategy, which is designed to achieve a break-out position in the rapidly growing industry of regulated medical waste processing. The annual market for regulated medical waste treatment and processing is $2 billion in the U.S. alone and MedClean possesses innovative technologies and provides unique solutions to meet the specific needs of the various segments of this market. The fundamentals of our strategic plan can be boiled down to three things: leadership, product and sales, and this letter addresses each of these topics. I am confident this letter will provide current and prospective shareholders with a comprehensive overview of the new MedClean Technologies."

About MedClean Technologies, Inc.

MedClean Technologies, Inc. is a provider of innovative technology and services for the onsite treatment and disposal of regulated medical waste. MedClean's flagship MedClean(R) Series systems are fully integrated, turnkey technology solutions that enable hospitals and other healthcare providers to safely, efficiently and cost-effectively convert bio-hazardous regulated medical waste into sterile, unrecognizable material suitable for disposal as municipal solid waste. MedClean was founded in 1997 with corporate headquarters, research and development and distribution facilities located in Bethel, Connecticut. Further information on MedClean can be found at and in filings with the Securities and Exchange Commission found at

Statements about our future expectations are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words "may," "will," "should," "anticipate," "believe," "appear," "intend," "plan," "expect," "estimate," "approximate," and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2007, filed with the SEC on March 31, 2008, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

    MedClean Technologies, Inc.               Investor Contact:
    Kevin Dunphy                              Cameron Donahue
    Chief Financial Officer                   Hayden IR
    (203) 798-1080                            (651) 653-1854

SOURCE MedClean Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MedClean Technologies Inc. Announces New Ticker Symbol
2. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
3. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
4. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
5. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
6. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
7. Advanced technologies aim to transform the coaching of top athletes
8. Global Med Technologies(R) Extends Its Worldwide Outreach
9. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
10. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
11. Neurobiological Technologies Reports Going Concern Qualification
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley ... Michigan boxing style concert posters. This is one of Joplin's most famous and beautiful ... at the University of Michigan in Ann Arbor. The According to Hawley, "It is ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at ... Michigan, have come together on Thanksgiving Day to share the things that they ... on the Serenity Point YouTube channel, patients displayed what they wrote on index ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent ... and the need to integrate dose form selection in early phase drug development. ... membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate ...
(Date:11/26/2015)... , ... November 26, 2015 , ... PRMA Plastic Surgery ... 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What ... up every day excited to rebuild lives and it’s an honor to have served ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... the "Radioimmunoassay Market by Type (Reagents ... Industry, Academics, Clinical Diagnostic Labs), Application (Research, ... to 2020" report to their offering. ... the addition of the "Radioimmunoassay Market ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... , Nov. 25, 2015 On Tuesday, ... federal bellwether trial against Wright Medical Technology, Inc. ... their Conserve metal-on-metal hip implant device, awarded $11 ... a two week trial and three days of ... hip device was defectively designed and unreasonably dangerous, ...
Breaking Medicine Technology: